Post-Marketing Surveillance Study To Observe Inlyta (Registered) Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
Phase of Trial: Phase IV
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 11 Oct 2016 Status changed from active, no longer recruiting to completed.
- 06 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
- 06 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.